MSB Trading 2020 - a new dawn, page-2720

This is a pioneering new area of therapy not yet approved in the US . It has to withstand cynicism . It is expensive . Significantly I have read articles saying getting people on to the trial is difficult as who wants to exclude other experimental available treatments by enrolling in a trial where you do not know if u r receiving the therapy or receiving standard care. Pity it is not being trialed in India or Brazil anywhere with huge hospitalizations. No way after all of this would I expect anything else but a continuation of the trial to get solid efficacy figures. Results have to show efficacy among a full range of patients etc. This is a speculative risky stock that I am on high alert with. No way would this news fit a sell for me.